Meta-analysis of the efficacy and safety of the combination of Drivarilumab and Tremelimumab in the treat-ment of metastatic non-small cell lung cancer
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
维普
万方数据
目的 系统评价度伐利尤单抗(durvalumab)联合曲美木单抗(tremelimumab)治疗转移性非小细胞肺癌(mNSCLC)的有效性和安全性.方法 计算机检索万方、中国知网、维普、The Cochrane Library、PubMed、Embase、Web of Science数据库,检索度伐利尤单抗与曲美木单抗联合治疗非小细胞肺癌的研究,检索范围自2000年1月1日至2023年11月28日.由不同的研究者独立进行文献筛选、数据提取、文献偏倚风险评估,对提取后的数据进行Meta分析.结果 与对照组相比,度伐利尤单抗与曲美木单抗联合治疗组的总生存率(OS)、无进展生存期(PFS),差异无统计学意义(P＞0.05);2组不良反应发生率比较,差异有统计学意义(P＜0.05).结论 相比于三联/传统疗法,度伐利尤单抗联合曲美木单抗治疗mNSCLC的不良反应较少.
Objective To systematically evaluate the efficacy and safety of durvalumab in combination with tremelimumab in the treatment of metastatic non-small cell lung cancer.Methods Wanfang,CNKI,and VIP,The Co-chrane Library,Pub Med,Embase,Web of Science databases were searched for studies of durvalumab in combination with tremelimumab in the treatment of non-small-cell lung cancer from 1st January 2000 to 28 th November 2023.Literature screening,data extraction,risk of bias assessment were performed independently by different researchers,and M eta-anal-ysis was performed on the extracted data.Results There was no significant difference in overall survival(OS),progres-sion-free survival(PFS),and a significant reduction in the incidence of adverse events in the combination treatment group of duvarizumab and trimethoprim compared with the control group.Conclusion Compared to triple/traditional therapy,the combination of Drivarilumab and Tremelimumab has fewer adverse reactions in the treatment of metastatic non-small cell lung cancer.
Carcinoma,non-small-cell lungAntibodies,monoclonalTreatment outcomeDrug-related side effects and adverse reactionsMeta-analysis
维普
万方数据
